Next Article in Journal
Prognostic and Predictive Relevance of Tumor-Infiltrating Lymphocytes in Squamous Cell Head–Neck Cancer Patients Treated with Radical Radiotherapy/Chemo-Radiotherapy
Previous Article in Journal
Extra-Pleural Pneumonectomy (EPP) in Children and Adults with Locally Advanced Sarcoma: A CanSaRCC Study
Case Report

Immunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case Report

1
Section of GI Oncology, Department of Medical Oncology, Houston Methodist Neal Cancer Center, Houston, TX 77030, USA
2
Cockrell Center of Advanced Therapeutics Phase I Program, Houston Methodist Research Institute, Houston, TX 77030, USA
3
Department of Internal Medicine, Weill Cornell Medical College, New York, NY 10021, USA
4
Cancer Clinical Trials, Houston Methodist Research Institute, Houston, TX 77030, USA
5
Department of Pharmacy, Houston Methodist Hospital, Houston, TX 77030, USA
6
Houston Methodist Radiology, Houston Methodist Hospital, Houston, TX 77030, USA
7
Section of Nephrology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
8
Sherrie and Alan Conover Center for Liver Disease and Transplantation, JC Walter Jr Center for Transplantation and Houston Methodist Hospital, Houston, TX 77030, USA
*
Authors to whom correspondence should be addressed.
Curr. Oncol. 2022, 29(6), 4267-4273; https://doi.org/10.3390/curroncol29060341
Received: 29 May 2022 / Revised: 9 June 2022 / Accepted: 12 June 2022 / Published: 15 June 2022
Systemic combination therapy of immune checkpoint inhibitors and vascular endothelial growth factors have provided the basis for improved outcomes in select patients with unresectable or metastatic hepatocellular carcinoma. However, for patients with resectable disease, surgery alone or an orthotopic liver transplant remains the standard of care. Within the realms of transplant oncology, neoadjuvant systemic therapy is currently being evaluated as a potential strategy to improve outcomes in patients with HCC. Here, we report excellent response with significant downstaging in a safe manner after neoadjuvant treatment with atezolizumab and bevacizumab in a patient diagnosed with poorly differentiated HCC. As a result of the significant response observed with safe outcomes, the patient was listed for orthotopic liver transplant (OLT) evaluation and transplanted successfully. View Full-Text
Keywords: transplant oncology; liver transplantation; hepatocellular carcinoma; immunotherapy; immune checkpoint inhibitors; CTLA-4 inhibitors; PD-1 inhibitors transplant oncology; liver transplantation; hepatocellular carcinoma; immunotherapy; immune checkpoint inhibitors; CTLA-4 inhibitors; PD-1 inhibitors
Show Figures

Figure 1

MDPI and ACS Style

Abdelrahim, M.; Esmail, A.; Umoru, G.; Westhart, K.; Abudayyeh, A.; Saharia, A.; Ghobrial, R.M. Immunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case Report. Curr. Oncol. 2022, 29, 4267-4273. https://doi.org/10.3390/curroncol29060341

AMA Style

Abdelrahim M, Esmail A, Umoru G, Westhart K, Abudayyeh A, Saharia A, Ghobrial RM. Immunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case Report. Current Oncology. 2022; 29(6):4267-4273. https://doi.org/10.3390/curroncol29060341

Chicago/Turabian Style

Abdelrahim, Maen, Abdullah Esmail, Godsfavour Umoru, Kiersten Westhart, Ala Abudayyeh, Ashish Saharia, and Rafik M. Ghobrial. 2022. "Immunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case Report" Current Oncology 29, no. 6: 4267-4273. https://doi.org/10.3390/curroncol29060341

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop